Anna Berkenblit
Director/Board Member presso SURROZEN, INC.
Patrimonio netto: 3 M $ in data 31/01/2024
Profilo
Anna Berkenblit is currently the Director at Surrozen Operating, Inc. and an Independent Director at Surrozen, Inc. She previously worked as the Chief Medical Officer & Senior Vice President at ImmunoGen, Inc., Vice President at Pfizer Inc., Vice President & Head-Clinical Research at AVEO Pharmaceuticals, Inc., and Senior Vice President-Clinical Development at H3 Biomedicine, Inc. Berkenblit received her graduate degrees from Harvard University and Massachusetts Institute of Technology, her undergraduate degree from Yale University, and her doctorate from Harvard Medical School.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
IMMUNOGEN, INC.
0.04% | 29/12/2023 | 101 612 ( 0.04% ) | 3 M $ | 31/01/2024 |
Posizioni attive di Anna Berkenblit
| Società | Posizione | Inizio |
|---|---|---|
| SURROZEN, INC. | Director/Board Member | 01/08/2018 |
Surrozen Operating, Inc.
 Surrozen Operating, Inc. BiotechnologyHealth Technology Surrozen Operating, Inc. operates as a biopharmaceutical company that focuses on harnessing the Wnt pathway for applications in regenerative medicine. The firm implements a surrogate Wnt platform with the potential to unlock stem cell control in an array of human tissues. The company was founded by K. Christopher Garcia, Roeland Nusse, Calvin J. Kuo, Hans Claudia and Claudia Janda in 2015 and is headquartered in South San Francisco, CA. | Director/Board Member | 14/03/2019 |
Precedenti posizioni note di Anna Berkenblit
| Società | Posizione | Fine |
|---|---|---|
| IMMUNOGEN, INC. | Chief Tech/Sci/R&D Officer | 31/08/2023 |
H3 Biomedicine, Inc.
 H3 Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The private company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa. | Corporate Officer/Principal | 01/01/2015 |
| AVEO PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 01/01/2013 |
| PFIZER, INC. | Corporate Officer/Principal | 01/09/2011 |
Formazione di Anna Berkenblit
| Harvard University | Graduate Degree |
| Massachusetts Institute of Technology | Graduate Degree |
| Yale University | Undergraduate Degree |
| Harvard Medical School | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 3 |
|---|---|
| IMMUNOGEN, INC. | Health Technology |
| PFIZER, INC. | Health Technology |
| SURROZEN, INC. | Health Technology |
| Aziende private | 3 |
|---|---|
AVEO Pharmaceuticals, Inc.
 AVEO Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology AVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA. | Health Technology |
H3 Biomedicine, Inc.
H3 Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The private company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa. | Health Technology |
Surrozen Operating, Inc.
Surrozen Operating, Inc. BiotechnologyHealth Technology Surrozen Operating, Inc. operates as a biopharmaceutical company that focuses on harnessing the Wnt pathway for applications in regenerative medicine. The firm implements a surrogate Wnt platform with the potential to unlock stem cell control in an array of human tissues. The company was founded by K. Christopher Garcia, Roeland Nusse, Calvin J. Kuo, Hans Claudia and Claudia Janda in 2015 and is headquartered in South San Francisco, CA. | Health Technology |
- Borsa valori
- Insiders
- Anna Berkenblit
